Equipoise (Boldenone): From Human Drug to Racehorse Standard, and Its Hematocrit Problem

Equipoise has an unusual origin story compared to most anabolic steroids discussed on this site: it was designed for humans first, discontinued from human medicine, and only became commercially significant after being repositioned as a veterinary drug — the opposite path of a compound like Masteron or Primobolan, both of which started in human oncology. Where Boldenone Came From Boldenone was patented by Ciba in 1949, making it one of the oldest synthetic testosterone-derived anabolic steroids — actually predating the more commonly cited "first" anabolic steroid, Dianabol, which is itself structurally derived from boldenone with an added methyl group for oral bioavailability. Ciba spent the 1950s and 1960s developing different ester attachments to extend boldenone's duration of action, eventually settling on the undecylenate ester. This compound was introduced for human clinical use under the brand name Parenabol in the 1960s. How It Was Actually Studied in Medicine Parenabol's human research focused on the same territory most early anabolic steroids were tested in: wasting conditions, weight loss, and growth disorders. According to PubMed, a 1971 Polish clinical study evaluated Parenabol specifically in children and adolescents with dwarfism, examining its effects on body height, body weight, and growth over time ([Stopczyk, Wiadomości Lekarskie, 1971, PMID: 5548725](https://pubmed.ncbi.nlm.nih.gov/5548725/)) — consistent with how many anabolic steroids of that era were explored as growth-promoting agents for short-stature children before more targeted growth hormone therapies existed. Ultimately, Parenabol didn't demonstrate enough advantage over other anabolic steroids already available, and it was discontinued from the human pharmaceutical market by the end of the 1970s — not pulled for a specific safety failure, but essentially outcompeted by other options within the same drug class. The Veterinary Pivot: How It Became Equipoise Squibb acquired the patent rights and re-launched boldenone undecylenate under the brand name Equipoise, positioned specifically as a veterinary drug for horses. This is where boldenone actually found its lasting commercial niche, and it remains in active veterinary use today. According to PubMed, real pharmacokinetic and drug-detection research has been conducted specifically on Equipoise administration in horses — one study developed methods to screen, confirm, and quantify boldenone metabolites in equine urine following a therapeutic dose, finding detectable metabolites from as early as 2 hours up to 42 days after administration ([Weidolf, Chichila & Henion, Journal of Chromatography, 1988, PMID: 3235575](https://doi.org/10.1016/s0378-4347(00)80580-0)), with a related study developing a more sensitive mass spectrometry method capable of detecting boldenone metabolites in equine urine up to 17 days post-administration ([Weidolf, Lee & Henion, Biomedical & Environmental Mass Spectrometry, 1988, PMID: 3365498](https://doi.org/10.1002/bms.1200150508)). This research exists specifically because Equipoise is used in real veterinary and competitive horse racing contexts, where anti-doping detection is an active, practical concern. The Mechanism: A Testosterone Derivative With Reduced Androgenicity Boldenone is a 1(2)-dehydrogenated analogue of testosterone — a structural modification of the testosterone molecule itself, rather than a DHT derivative like Masteron or Primobolan. It functions as an androgen receptor agonist, and is generally characterized as having anabolic potency similar to testosterone while carrying comparatively lower androgenic potency — part of why it developed a reputation as a "cleaner" option relative to testosterone itself in terms of androgenic side effects, while still producing meaningful muscle-building activity through the same receptor mechanism as any other AAS. The Hematocrit Problem This is where Equipoise connects directly to a mechanism covered in more depth in our dedicated article on TRT and hematocrit — androgens stimulate erythropoietin production and red blood cell synthesis, and this effect isn't unique to testosterone itself. According to PubMed, a review of thrombotic complications from anabolic-androgenic steroid use describes androgen-induced polycythemia as one of several converging mechanisms (alongside platelet hyperaggregability and procoagulant shifts in clotting proteins) that predispose AAS users to both venous and arterial thrombosis ([Gurumurthy & Thachil, Research and Practice in Thrombosis and Haemostasis, 2025, PMID: 41229672](https://doi.org/10.1016/j.rpth.2025.103208)). The real-world stakes of this aren't abstract. According to PubMed, a detailed case report described a 38-year-old recreational bodybuilder with years of supraphysiologic androgen use who developed progressive polycythemia (hematocrit 56.9%, well above the normal threshold), anabolic steroid-induced cardiomyopathy, and severe cardiovascular symptoms. Despite recurrent therapeutic phlebotomy, guideline-based cardiac treatment, and a structured medical protocol to support androgen discontinuation, the patient died from a cardiovascular event more than a year after stopping steroid use entirely ([Magnolini et al., Harm Reduction Journal, 2025, PMID: 40841640](https://doi.org/10.1186/s12954-025-01294-w)) — a sobering illustration that this isn't a minor lab abnormality to manage casually. It's worth being precise about what is and isn't specifically documented for boldenone: the general AAS-class mechanism linking androgen use to erythrocytosis is well established in the literature above, but dedicated human clinical trials measuring boldenone's hematocrit effect specifically (as opposed to testosterone or AAS use broadly) don't appear in the indexed research. Boldenone is frequently discussed anecdotally within bodybuilding and clinical harm-reduction communities as having a particularly pronounced tendency toward hematocrit elevation, plausibly related to its comparatively low aromatization (similarly to how our TRT and hematocrit article discusses non-aromatizing compounds carrying this reputation) — but this specific claim rests more on clinical observation and community-reported pattern than on a dedicated boldenone-specific trial in the peer-reviewed literature. What Bodybuilders Commonly Combine It With Within bodybuilding use, Equipoise is rarely used as a sole compound. It's most commonly discussed alongside a testosterone base — the rationale given is that Equipoise's own androgenic activity is considered insufficient on its own to prevent the symptoms of suppressed natural testosterone production that accompanies any AAS use, so a testosterone-containing compound is typically included specifically to maintain baseline androgenic function rather than relying on Equipoise to serve both roles. Beyond a testosterone base, it's also frequently discussed in combination with other anabolic compounds selected for complementary effects (commonly agents perceived as adding more direct strength or mass alongside Equipoise's comparatively moderate, steadier anabolic profile) — though the specific compounds paired with it vary widely across individual use patterns and aren't governed by any standardized protocol. The Bottom Line Equipoise's history runs in an unusual direction compared to most anabolic steroids covered on this site — designed and clinically tested in humans first, discontinued from human medicine for lack of clear advantage over existing options, and only becoming commercially significant after being repositioned as a veterinary drug for horses, where it remains in active use today with real, ongoing pharmacokinetic and detection research behind it. Its androgen-receptor mechanism carries the same class-wide hematocrit and thrombotic risk documented across anabolic steroids generally, even though boldenone-specific human hematocrit data is thinner than the general class-wide research. As with every compound covered in this category, it remains a Schedule III controlled substance in the U.S. with no approved human medical use today.